Marucci Anthony S
Known title: PRESIDENT & CEOCIK: 0001429933
Marucci Anthony S's purchase track record
Marucci Anthony S has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/11/2024 | CLDX | $308K | -17.9% | -23.0% | -2.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CLDX | ▲ Buy | Open Market | 11,500 | $308K | 11/11/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 75,000 | $208K | 8/15/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 45,000 | $406K | 8/15/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 120,000 | $4.5M | 8/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.